日韩情欲综合福利久久电影_榴莲视频在线观看卍_夜色福利院在线观看_国产精品 不卡_无码精品人妻一区二区三区在线_99韩国日本欧美国产_欧美一级特黄大片做受_午夜福利麻豆精品_人妻AV无码系列一_亚洲Aⅴ天堂Av天堂无码不卡

Industry Dynamics

Industry News

08-03

2020

MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX?

Aug. 4, 2020 -- MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce that the Europea……

07-28

2020

European Commission approves third nintedanib indication in pulmonary fibrosis

July25, 2020 ? Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases……

07-10

2020

Novartis receives EC approval for Enerzair? Breezhaler?, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU

July 7, 2020 ― Novartis today announced that the European Commission (EC) has approved Enerzair? Breezhaler? (QVM249; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance trea……

06-29

2020

FDA Approves First Therapy for Rare Disease that Causes Low Phosphate Blood Levels, Bone Softening

June 28, 2020-- Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by……

06-05

2020

BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

June 02, 2020 - AstraZeneca’s BRILINTA? (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of hear……

05-29

2020

FDA Approves First Treatment for a Form of Bladder Dysfunction in Pediatric Patients as Young as 2 Years of Age

May 26, 2020-- The U.S. Food and Drug Administration today granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), a ……

< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 >

Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1